iQ-008 is a novel analgesic being investigated as a non-addictive therapeutic for neuropathic pain
Princeton, New Jersey, July 1, 2022 - iQure Pharma Inc. (iQure), a US-based global biotech company, confirms that its lead asset, iQ-008, a novel analgesic compound, is progressing to the next stage in the Preclinical Screening Platform for Pain (PSPP) as part of the National Institutes of Health (NIH) HEAL Initiative (Helping to End Addiction Long-term).
The PSPP program offers testing that includes an assessment of in vitro and pharmacokinetic and side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.
“This is very good news and an important step in the development of iQ-008 as a promising therapeutic,” said iQure Chief Executive Officer Pawel Zolnierczyk. “With this ongoing support from NIH, we will be able to further our understanding of iQ-008’s profile, which will contribute to the progression of iQ-008 as an Investigational New Drug (IND).”
iQure researchers developed iQ-008 as a therapeutic for neuropathic pain, in response to the more than 25 million Americans who live with chronic pain and are forced to rely solely on potentially addictive opioid medications for pain management.
About iQure Pharma
A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for neuropathic pain. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.